Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, Giovanna Esposito, Claudio Dazzi, Luigi Cavanna, Marco Angelo Burgio, Francesco Rosetti, Simona Rizzato, Floriana Morgillo, Saverio Cinieri, Antonello Veccia, Maximilan Papi, Giuseppe Tonini, Vittorio Gebbia, Serena Ricciardi, Daniele Pozzessere, Alessandra Ferro, Claudia Proto, Raffaele Costanzo, Manolo D’Arcangelo, Manuela Proietto, Piera Gargiulo, Raimondo Di Liello, Laura Arenare, Filippo De Marinis, Lucio Crinò, Fortunato Ciardiello, Nicola Normanno, Ciro Gallo, Francesco Perrone, Cesare Gridelli, Alessandro Morabito
Publikováno v:
Journal of Thoracic Oncology. 17:1086-1097
Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were available in non-Asian patients. BEVERLY is an Italian, multicenter, randomize
Autor:
Yi-Long Wu, Ying Cheng, Jianying Zhou, Shun Lu, Yiping Zhang, Jun Zhao, Dong-Wan Kim, Ross Andrew Soo, Sang-We Kim, Hongming Pan, Yuh-Min Chen, Chih-Feng Chian, Xiaoqing Liu, Daniel Shao Weng Tan, Rolf Bruns, Josef Straub, Andreas Johne, Jürgen Scheele, Keunchil Park, James Chih-Hsin Yang, Zhe Liu, Xi Chen, Mengzhao Wang, Shiying Yu, Helong Zhang, Jian Fang, Wei Li, Chih-Hsin Yang, Gee-Chen Chang, Te-Chun Hsia, Cheng-Ta Yang, Chin-Chou Wang, Byoung Chul Cho, Ki Hyeong Lee, Young-Chul Kim, Ho Jung An, In Sook Woo, Jae Yong Cho, Sang Won Shin, Jong-Seok Lee, Joo-Hang Kim, Seung Soo Yoo, Terufumi Kato, Naofumi Shinagawa, Shao Weng Daniel Tan, Lynette Si-Mien Ngo, Kananathan Ratnavelu, Azura Rozila Ahmad, Chong Kin Liam, Filippo de Marinis, Pierfrancesco Tassone, Amelia Insa Molla, Antonio Calles Blanco, Martin Emilio Lazaro Quintela, Enriqueta Felip Font, Anne-Marie Dingemans, Lynne Bui
Publikováno v:
The Lancet Respiratory Medicine. 8:1132-1143
Summary Background We evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexp
Autor:
Antonio Rossi, Francesco Perrone, Filippo de Marinis, Fortunato Ciardiello, Agnese Montanino, Cesare Gridelli, Floriana Morgillo, Nicola Normanno, Ciro Gallo, Gennaro Daniele, Lucio Crinò, Maria Carmela Piccirillo, Alessandro Morabito
Publikováno v:
Clinical Lung Cancer. 17:461-465
BACKGROUND: About 20% of advanced non-small-cell lung cancer (NSCLC) cases harbor somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene. In these patients, the standard first-line treatments are the EGFR-
Autor:
Elena Guerini-Rocco, Caterina Fumagalli, Massimo Barberis, Filippo de Marinis, Davide Vacirca, Antonio Passaro
Publikováno v:
Immunotherapy. 10(12)
Autor:
Filippo de Marinis, Catherine Dubos-Arvis, Pablo Perez-Moreno, Enric Carcereny, Ali Zeaiter, Alain Vergnenegre, Antonio Passaro, Rafael Rosell, Ana Drozdowskyj
Publikováno v:
Future Oncology. 11:421-429
ABSTRACT Aim: This analysis investigates incidence and time course of rash in the EURTAC study. Materials & methods: Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycle
Autor:
Filippo de Marinis, Antonio Passaro
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(8)
Autor:
Rodryg Ramlau, Filippo de Marinis, Keunchil Park, José Rodrigues Pereira, Luis Paz-Ares, Joachim von Pawel, Maciej Krzakowski, Karl Maria Schumacher, Anja von Heydebreck, Ilhan Celik, Robert Pirker, Wilfried Eberhardt, Kenneth J. O'Byrne, S. Störkel
Findings from the phase 3 First-Line ErbituX in lung cancer (FLEX) study showed that the addition of cetuximab to first-line chemotherapy significantly improved overall survival compared with chemotherapy alone (hazard ratio [HR] 0·871, 95% CI 0·76
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7db6a818a96993e37ad6749cc8843b0
https://www.ncbi.nlm.nih.gov/pubmed/22056021
https://www.ncbi.nlm.nih.gov/pubmed/22056021
Publikováno v:
The Lancet Oncology. 15:e148-e149
Publikováno v:
I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]. 1(6)